Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 7/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | COMT | P21964 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CNOT7 | Q9UIV1 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6928442 | 0.90 | CYP11B1 (0.56) | CYP11B1CYP11B2IDO1POLBCOMT | |
| SCHEMBL6925358 | 0.84 | CYP11B1 (0.57) | CYP11B1CYP11B2KDM1AHDAC6 | |
| SCHEMBL6599405 | 0.84 | CYP11B1 (0.58) | CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL6601220 | 0.84 | CYP11B1 (0.57) | CYP11B1CYP11B2 | |
| SCHEMBL6599385 | 0.84 | CYP11B1 (0.48) | CYP11B1CYP11B2 | |
| SCHEMBL3079356 | 0.83 | CYP11B1 (0.71) | CYP11B1CYP11B2HTTIDO1POLB | |
| SCHEMBL6599521 | 0.82 | CYP11B1 (0.43) | CYP11B1CYP11B2IDO1HDAC6 | |
| SCHEMBL6926992 | 0.82 | CYP11B1 (0.45) | CYP11B1CYP11B2IDO1KMT2A | |
| SCHEMBL6921791 | 0.82 | HRH3 (0.46) | CYP11B1CYP11B2HDAC6 | |
| SCHEMBL14415972 | 0.82 | CYP11B1 (0.50) | CYP11B1CYP11B2HTTIDO1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117362237-A | Synthesis method of etomidate | 化学与精细化工广东省实验室 | 2024-01-09 | — | — | CN | claimed |
| CN-117362237-A | Synthesis method of etomidate | 化学与精细化工广东省实验室 | 2024-01-09 | — | — | CN | disclosed |
| CN-117362237-A | Synthesis method of etomidate | 化学与精细化工广东省实验室 | 2024-01-09 | — | — | CN | disclosed |
| EP-1169320-B1 | FARNESYL TRANSFERASE INHIBITORS HAVING A PYRROLE STRUCTURE AND PROCESS FOR PREPARATION THEREOF | LG CHEM INVESTMENT LTD (KR) | 2004-09-22 | — | — | EP | disclosed |
| EP-1045846-B1 | IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF | LG CHEMICAL LTD (KR) | 2003-05-02 | — | — | EP | disclosed |
| US-6518429-B2 | Anticancer agents, treating restenosis, atherosclerosis and hepatitis virus | LG CHEMICAL, LTD. (KR) | 2003-02-11 | — | — | US | disclosed |
| US-6511978-B1 | For treating cancer, restenosis, atherosclerosis or viral infections | LG LIFE SCIENCES, LTD. (KR) | 2003-01-28 | — | — | US | disclosed |
| US-6472526-B1 | SHOWS AN INHIBITORY ACTIVITY AGAINST FARNESYL TRANSFERASE OR PHARMACEUTICALLY ACCEPTABLE SALTS OR ISOMERS THEREOF, IN PHARMACEUTICAL COMPOSITION AND INTERMEDIATES | LG CHEMICAL LTD. (KR) | 2002-10-29 | — | — | US | disclosed |
| US-20020137769-A1 | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof | LG CHEMICAL LTD. | 2002-09-26 | — | — | US | disclosed |
| US-6268363-B1 | ANTITUMOR | LG CHEMICAL LTD. (KR) | 2001-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137769-A1 | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof | FNTA, FNTB, FDPS | CYP11B1 74/4885CYP11B2 110/4885HTT 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.